Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...
BioAge just completed its IPO to continue funding clinical trials, but competition will be stiff. BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.
BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based ...
Morgan Stanley and Goldman Sachs issued bullish notes on BioAge (NASDAQ:BIOA) based on the company’s drug candidate azelaprag that aims to increase weight-loss while improving body composition ...
Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. RICHMOND, Calif., Sept. 25, 2024 (GLOBE ...
BioAge Labs is a new kid on the block. The company completed its initial public offering (IPO) on Oct. 1. The biotech's leading candidate is called azelaprag. It is being developed as a weight ...
2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback